USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ALTRAVAX, INC.
Address: 3233 15TH ST S
FARGO, ND
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,595,625.00 6

Award List:

VLP-Based Antibody-Inducing Vaccines for HIV-1

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert G. Whalen
Award Amount: $599,688.00
Abstract:
DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with mon omeric recombinant forms of viral envelope… More

Improved Vaccines for Influenza B Virus

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert G. Whalen
Award Amount: $598,391.00
Abstract:
DESCRIPTION (provided by applicant): Influenza is a major cause of morbidity and mortality around the world. In the United States, seasonal epidemics of flu occur from late fall to early spring affecting all age groups but with especially high rates of in fection in children. Serious illness and… More

Designing Improved HIV-1 Envelope Proteins as Vaccine Candidates

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert G. Whalen
Award Amount: $599,074.00
Abstract:
DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with mon omeric recombinant forms of viral envelope… More

Novel Tetravalent Vaccines for Dengue Virus

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert G. Whalen – 650-200-5789
Award Amount: $598,472.00
Abstract:
DESCRIPTION (provided by applicant): Dengue virus infection is an emerging disease and an expanding global health problem. More than one-third of the world's population is at risk for transmission in tropical and subtropical areas and vaccines are an urgent public health priority. Although… More

Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert G. Whalen – 650-200-5789
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Vaccines are urgently needed to slow the spread of the HIV/AIDS epidemic, and immunogens that can induce neutralizing antibodies remain an important goal of vaccine research. An increasing number of human monoclonal antibodies (mAbs) have been isolated in recent… More

Novel Therapeutic Vaccines for Chronic HBV

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Robert G. Whalen – 650-200-5789
Award Amount: $600,000.00
Abstract:
DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) is a noncytopathic, hepatotropic DNA virus that results in a self-limited acute infection in a majority of otherwise healthy individuals but can also cause chronic infection, particularly in newborns infected by vertical transmission.… More